Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System.
Ji Y, Calonder C, Kirsilä T, Burciu A, Tisu M, Joubert Y, Laurent N, Hua E, Patekar M, Drollmann A, Woessner R. Ji Y, et al. Among authors: drollmann a. Pharmaceutics. 2023 Sep 1;15(9):2266. doi: 10.3390/pharmaceutics15092266. Pharmaceutics. 2023. PMID: 37765235 Free PMC article.
Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis.
Staubach P, Alvaro-Lozano M, Sekerel BE, Maurer M, Ben-Shoshan M, Porter M, Hua E, Ji Y, Burciu A, Savelieva M, Severin T, Drollmann A, Bienczak A. Staubach P, et al. Among authors: drollmann a. Pediatr Allergy Immunol. 2023 Jul;34(7):e13982. doi: 10.1111/pai.13982. Pediatr Allergy Immunol. 2023. PMID: 37492920 Clinical Trial.
Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.
Schiller H, Huth F, Schuhler C, Drollmann A, Kaul M, Woessner R, Shah B, Weis W, End P. Schiller H, et al. Among authors: drollmann a. Eur J Pharm Sci. 2022 May 1;172:106155. doi: 10.1016/j.ejps.2022.106155. Epub 2022 Mar 3. Eur J Pharm Sci. 2022. PMID: 35247543 Free article.
Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.
Singh D, Wild JM, Saralaya D, Lawson R, Marshall H, Goldin J, Brown MS, Kostikas K, Belmore K, Fogel R, Patalano F, Drollmann A, Machineni S, Jones I, Yates D, Tillmann HC. Singh D, et al. Among authors: drollmann a. Respir Res. 2022 Feb 10;23(1):26. doi: 10.1186/s12931-022-01949-3. Respir Res. 2022. PMID: 35144620 Free PMC article. Clinical Trial.
Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects.
Vaidya S, Jauernig J, Ethell B, Abdallah N, Machineni S, Drollmann A, Heudi O, Last S, Hahn M, Radhakrishnan R, Ignatenko S, Tillmann HC. Vaidya S, et al. Among authors: drollmann a. Pulm Pharmacol Ther. 2020 Oct;64:101964. doi: 10.1016/j.pupt.2020.101964. Epub 2020 Oct 6. Pulm Pharmacol Ther. 2020. PMID: 33035700 Free article. Clinical Trial.
Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.
Gauvreau GM, Arm JP, Boulet LP, Leigh R, Cockcroft DW, Davis BE, Mayers I, FitzGerald JM, Dahlen B, Killian KJ, Laviolette M, Carlsten C, Lazarinis N, Watson RM, Milot J, Swystun V, Bowen M, Hui L, Lantz AS, Meiser K, Maahs S, Lowe PJ, Skerjanec A, Drollmann A, O'Byrne PM. Gauvreau GM, et al. Among authors: drollmann a. J Allergy Clin Immunol. 2016 Oct;138(4):1051-1059. doi: 10.1016/j.jaci.2016.02.027. Epub 2016 Apr 7. J Allergy Clin Immunol. 2016. PMID: 27185571 Clinical Trial.
27 results